Keywords: Regeneron, Financial results 2012, Eylea, Zaltrap

Regeneron posts strong growth for 2012, beating analysts' estimates

Article | 15 February 2013

Print This

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) yesterday announced that total revenues were $415 million in the fourth quarter ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in